Incyte: A Good Company Facing Irrelevant Investors’ Reaction
Incyte decided to stop an early ongoing trial of a combination treatment ruxolitinib (Incyte) plus regorafenib (Bayer) for colon cancer after observing the combination wasn’t working. Both drugs are approved for different indications and both are doing well in the market. At this moment in the market chaos, this news looked as if a terrible thing that must cause an unwarranted selloff in the stock.
Incyte (INCY) ruxolitinib is already approved for myelofibrosis and polycythemia vera and the Company has several different drugs . . .
This content is for paid subscribers.
Today’s Highlights January 28, 2016